sSLAMF7 is thought to bind SLAMF7 on myeloma cells, leading to tumor cell growth, and sSLAMF7-positivity was associated with R-ISS stage III, which may in turn be associated with a lower good response rate, as shown in Table 2. This evidence concerns the gene SLAMF7 and plasma cell myeloma.